KalVista Pharmaceuticals Future Growth

Future criteria checks 2/6

KalVista Pharmaceuticals is forecast to grow earnings and revenue by 57.2% and 49.7% per annum respectively while EPS is expected to grow by 58.8% per annum.

Key information

57.2%

Earnings growth rate

58.8%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	49.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	16 Apr 2024

Recent future growth updates

Recent updates

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Feb 14

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Jan 30

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Oct 04

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

May 02

KalVista: Another Setback But The Key Value Driver Is Still In Place

Oct 14

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Sep 24

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

May 18

Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

Feb 02

We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

Sep 24

We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely

Jul 02

KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study

Jun 07

KalVista Pharmaceuticals names new medical chief

May 03

How Much Did KalVista Pharmaceuticals' (NASDAQ:KALV) CEO Pocket Last Year?

Mar 01

Estimating The Fair Value Of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Feb 03

Earnings and Revenue Growth Forecasts

NasdaqGM:KALV - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
4/30/2027	151	-5	43	57	3
4/30/2026	117	-27	-37	-62	4
4/30/2025	16	-110	-103	-134	5
4/30/2024	N/A	-114	-138	-102	6
1/31/2024	N/A	-108	-97	-97	N/A
10/31/2023	N/A	-101	-79	-78	N/A
7/31/2023	N/A	-95	-80	-79	N/A
4/30/2023	N/A	-93	-76	-75	N/A
1/31/2023	N/A	-91	-81	-79	N/A
10/31/2022	N/A	-92	-86	-84	N/A
7/31/2022	N/A	-89	-85	-83	N/A
4/30/2022	N/A	-82	-79	-78	N/A
1/31/2022	N/A	-73	-63	-62	N/A
10/31/2021	N/A	-61	-57	-56	N/A
7/31/2021	N/A	-52	-45	-44	N/A
4/30/2021	N/A	-46	-30	-30	N/A
1/31/2021	4	-38	-32	-32	N/A
10/31/2020	5	-37	-37	-37	N/A
7/31/2020	9	-33	-37	-37	N/A
4/30/2020	13	-29	-45	-45	N/A
1/31/2020	12	-31	-43	-43	N/A
10/31/2019	14	-26	-41	-40	N/A
7/31/2019	16	-23	-42	-41	N/A
4/30/2019	16	-21	-37	-36	N/A
1/31/2019	18	-13	-34	-32	N/A
10/31/2018	16	-14	5	7	N/A
7/31/2018	12	-16	7	9	N/A
4/30/2018	8	-16	9	11	N/A
1/31/2018	4	-19	14	14	N/A
10/31/2017	2	-22	N/A	-26	N/A
7/31/2017	1	-21	N/A	-23	N/A
4/30/2017	2	-21	N/A	-24	N/A
1/31/2017	2	-23	N/A	-23	N/A
10/31/2016	2	-18	N/A	-15	N/A
7/31/2016	2	-18	N/A	-15	N/A
4/30/2016	2	-15	N/A	-13	N/A
4/30/2015	2	-9	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KALV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KALV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KALV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KALV's revenue (49.7% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: KALV's revenue (49.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KALV's Return on Equity is forecast to be high in 3 years time

KalVista Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 7.6% to US$20.80

Consensus revenue estimates fall by 58%

Price target decreased to US$21.83

Price target decreased to US$32.83

No longer forecast to breakeven

Price target decreased to US$41.67

Recent updates

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

New minor risk - Share price stability

CEO & Director exercised options and sold US$351k worth of stock

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

New minor risk - Shareholder dilution

CEO & Director recently sold US$876k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

KalVista Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $160.125 million.

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

New major risk - Financial position

CEO & Director exercised options and sold US$122k worth of stock

Price target increased by 7.6% to US$20.80

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Independent Director notifies of intention to sell stock

CEO & Director exercised options and sold US$160k worth of stock

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

Consensus revenue estimates fall by 58%

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

CEO & Director exercised options and sold US$57k worth of stock

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

Price target decreased to US$21.83

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista: Another Setback But The Key Value Driver Is Still In Place

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Price target decreased to US$32.83

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

CEO & Director notifies of intention to sell stock

KalVista Pharmaceticals GAAP EPS of -$0.94

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

KalVista reaches five-month high as rival tumbles on hereditary angioedema

No longer forecast to breakeven

KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11

Price target decreased to US$41.67

KalVista Pharmaceuticals, Inc. Announces Board Changes

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

Price target decreased to US$46.71

Price target decreased to US$46.17

KalVista Pharmaceuticals, Inc. Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief from HAE Attacks in Patients

KalVista Pharmaceuticals, Inc. to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

Chief Scientific Officer exercised options to buy US$718k worth of stock.

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

U.S. Food and Drug Administration Lifts the Clinical Hold on Kalvista Pharmaceuticals, Inc.’s Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema